These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15797125)

  • 1. Revised structures for the capsular polysaccharides from Staphylococcus aureus Types 5 and 8, components of novel glycoconjugate vaccines.
    Jones C
    Carbohydr Res; 2005 May; 340(6):1097-106. PubMed ID: 15797125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Staphylococcus aureus infections: advances in vaccine development.
    Shinefield HR; Black S
    Expert Rev Vaccines; 2005 Oct; 4(5):669-76. PubMed ID: 16221068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
    Fattom A; Fuller S; Propst M; Winston S; Muenz L; He D; Naso R; Horwith G
    Vaccine; 2004 Dec; 23(5):656-63. PubMed ID: 15542186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests.
    Verdier I; Durand G; Bes M; Taylor KL; Lina G; Vandenesch F; Fattom AI; Etienne J
    J Clin Microbiol; 2007 Mar; 45(3):725-9. PubMed ID: 17202275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.
    Wacker M; Wang L; Kowarik M; Dowd M; Lipowsky G; Faridmoayer A; Shields K; Park S; Alaimo C; Kelley KA; Braun M; Quebatte J; Gambillara V; Carranza P; Steffen M; Lee JC
    J Infect Dis; 2014 May; 209(10):1551-61. PubMed ID: 24308931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-Acetylation is essential for functional antibody generation against Staphylococcus aureus capsular polysaccharide.
    Scully IL; Pavliak V; Timofeyeva Y; Liu Y; Singer C; Anderson AS
    Hum Vaccin Immunother; 2018 Jan; 14(1):81-84. PubMed ID: 29182428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
    Fattom AI; Sarwar J; Basham L; Ennifar S; Naso R
    Infect Immun; 1998 Oct; 66(10):4588-92. PubMed ID: 9746554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination and passive immunisation against Staphylococcus aureus.
    Schaffer AC; Lee JC
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S71-8. PubMed ID: 18757184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.
    Nanra JS; Timofeyeva Y; Buitrago SM; Sellman BR; Dilts DA; Fink P; Nunez L; Hagen M; Matsuka YV; Mininni T; Zhu D; Pavliak V; Green BA; Jansen KU; Anderson AS
    Vaccine; 2009 May; 27(25-26):3276-80. PubMed ID: 19200819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staphylococcus aureus antigens and challenges in vaccine development.
    Middleton JR
    Expert Rev Vaccines; 2008 Aug; 7(6):805-15. PubMed ID: 18665778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
    Ho MM; Bolgiano B; Martino A; Kairo SK; Corbel MJ
    Hum Vaccin; 2006; 2(3):89-98. PubMed ID: 17012902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic approaches against Staphylococcus aureus.
    Verkaik NJ; van Wamel WJ; van Belkum A
    Immunotherapy; 2011 Sep; 3(9):1063-73. PubMed ID: 21913829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillin-resistant Staphylococcus aureus.
    Roth DM; Senna JP; Machado DC
    Genet Mol Res; 2006 Aug; 5(3):503-12. PubMed ID: 17117366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus.
    von Eiff C; Taylor KL; Mellmann A; Fattom AI; Friedrich AW; Peters G; Becker K
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):297-302. PubMed ID: 17376630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?
    Projan SJ; Nesin M; Dunman PM
    Curr Opin Pharmacol; 2006 Oct; 6(5):473-9. PubMed ID: 16870507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full NMR assignment and revised structure for the capsular polysaccharide from Streptococcus pneumoniae type 15B.
    Jones C; Lemercinier X
    Carbohydr Res; 2005 Feb; 340(3):403-9. PubMed ID: 15680595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.
    Robbins JB; Schneerson R; Horwith G; Naso R; Fattom A
    Am Heart J; 2004 Apr; 147(4):593-8. PubMed ID: 15077073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full assignment of the 1H and 13C spectra and revision of the O-acetylation site of the capsular polysaccharide of Streptococcus pneumoniae Type 33F, a component of the current pneumococcal polysaccharide vaccine.
    Lemercinier X; Jones C
    Carbohydr Res; 2006 Jan; 341(1):68-74. PubMed ID: 16297895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic carbohydrate-based vaccines: challenges and opportunities.
    Mettu R; Chen CY; Wu CY
    J Biomed Sci; 2020 Jan; 27(1):9. PubMed ID: 31900143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polysaccharide of Alloiococcus otitidis, a new pathogen of otitis media: chemical structure and synthesis of a neoglycoconjugate thereof.
    Arar S; Vinogradov E; Shewmaker PL; Monteiro MA
    Carbohydr Res; 2008 May; 343(6):1079-90. PubMed ID: 18336800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.